Kariya Pharmaceuticals ApS

Q: What is the CVR number of Kariya Pharmaceuticals ApS?

Kariya Pharmaceuticals ApS is registered with CVR / Virk under CVR 39270684.

Q: Who is the chairman of Kariya Pharmaceuticals ApS?

Ian Rodney Laquian chairs the board of Kariya Pharmaceuticals ApS, in role since 2023.

Q: Where is Kariya Pharmaceuticals ApS headquartered?

Kariya Pharmaceuticals ApS's registered address is Ole Maaløes Vej 3.

APSActiveAdvertising protection

CVR 39270684Ole Maaløes Vej 3, 2200 København NResearch and experimental development on natural sciences and engineering· NACE 7210Est. 2018 · 8 years old0 employeeshttps://www.kariyapharma.com

Overview

Kariya Pharmaceuticals ApS is a Danish APS based in København N, operating in the Research and experimental development on natural sciences and engineering sector. Incorporated in 2018, the company has 0 employees and reported a gross profit of -DKK 32.1m in its latest annual filing.

Gross profit 2025

-32.1M DKK

+785% vs 2024

EBITDA margin (of gross profit)

101.8 %

−653% vs 2024

Net profit 2025

-26.5M DKK

-919% vs 2024

Key ratios

See full ratios →

-64.7 %

Very weak

Among the 10% lowest rated companies in the industry

20212025

0.6×

Very weak

Among the 20% lowest rated companies in the industry

20212025

-68.0 %

Very weak

Among the 10% lowest rated companies in the industry

20212025

EBITDA — year on year

DKK millions

Key figures

Annual report 2025

Gross profit	-32.1M DKK	+785%
EBITDA	-32.7M DKK	-653%
Net profit	-26.5M DKK	-919%
Total assets	38.9M DKK	+1591%
Equity	-25.2M DKK	-2064%
Employees	0	—

Contact

Address

Ole Maaløes Vej 3, 2200 København N

Website

https://www.kariyapharma.com

Advertising protection

Active — opted out of marketing use

Risika for professionals

Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.

Visit risika.com

Financial development

In its most recent annual report (2025), Kariya Pharmaceuticals ApS reported a gross profit of -DKK 32.1m. The figures on this page draw on 5 annual filings covering 2021 to 2025. The bottom line showed a net loss of DKK 26.5m.

At the end of 2025, current assets covered short-term debt 0.6 times. Kariya Pharmaceuticals ApS is one of 2 companies registered under Research and experimental development on natural sciences and engineering in Denmark.

Financials

Gross profit

DKK millions

EBITDA

DKK millions

Income statement

DKK thousands

Item	2025	2024	2023	2022	2021
Gross profit	-32,093	-3,625	-10,223	-13,798	-2,712
Staff expenses	-583	-716	-67	-14	-506
EBITDA	-32,676	-4,341	-10,290	-13,812	-3,218
Depreciation & amort.	-0	-0	-0	-8	-8
EBIT	-32,676	-4,341	-10,290	-13,820	-3,226
Net financials	-75	-207	-1,604	-805	-644
Profit before tax	-32,751	-4,548	-11,893	-14,625	-3,869
Tax	-6,261	-1,948	-3,871	-619	-614
Net profit	-26,490	-2,599	-8,023	-14,006	-3,255

Get a credit rating – not just the numbers

Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.

See the credit rating

Balance sheet

DKK thousands

Item	2025	2024	2023	2022	2021
Total assets	38,945	2,304	2,051	2,205	1,052
Equity	-25,207	1,284	-6,388	-26,732	-12,726
Long-term debt	0	0	0	11,887	11,321
Short-term debt	64,151	1,020	8,440	17,050	2,458
Total debt	64,151	1,020	8,440	28,937	13,778

Financial ratios

5-year trend

EBITDA margin (of gross profit)

<−999 %

20212025

Equity ratio

-64.7 %

Very weak

Among the 10% lowest rated companies in the industry

20212025

Return on equity

—

20212025

Net profit margin (of gross profit)

<−999 %

20212025

Asset turnover (of gross profit)

-0.82×

20212025

Debt / equity

—

20212025

Sector performance

17 of 28 ratios graded

28 financial ratios from the latest filing, each graded against companies in the same industry.

Profitability

Return on assets (ROA)Very weak

Among the 10% lowest rated companies in the industry

Net profit as a percentage of total assets — the return generated on the capital employed.

Basic earning power (BEP)Very weak

Among the 10% lowest rated companies in the industry

EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.

Capacity ratioVery weak

Among the 10% lowest rated companies in the industry

Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.

Gross marginNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.

Operating marginNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.

Net profit marginNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

The profit for the year as a share of revenue — the company's ability to turn revenue into profit.

Return on equity (ROE)Not rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Net profit as a percentage of equity — the return the owners earned on their invested capital this year.

Return on net assets (RONA)Not rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.

Liquidity

Current ratioVery weak

Among the 20% lowest rated companies in the industry

Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.

Quick ratioVery weak

Among the 20% lowest rated companies in the industry

Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.

Cash ratioVery weak

Among the 10% lowest rated companies in the industry

Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.

Cash conversion ratioAverage

Around the average of companies in the same industry

Cash flow relative to profit — the ability to convert reported profits into accessible cash.

Current assets to equityNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.

Fixed assets to long-term capitalNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.

Debt & solvency

Solidity ratioVery weak

Among the 10% lowest rated companies in the industry

Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.

Debt ratioVery weak

Among the 10% lowest rated companies in the industry

Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.

Income to debtVery weak

Among the 20% lowest rated companies in the industry

Profit relative to debt — the ability to create earnings while operating with debt.

EBITDA to debtVery weak

Among the 20% lowest rated companies in the industry

EBITDA relative to debt — how much operating earnings are available to service the debt.

Interest coverageVery weak

Among the 10% lowest rated companies in the industry

The ability to pay the interest on the company's debt out of its earnings.

Interest rate on debtStrong

Among the 40% highest rated companies in the industry

Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.

Interest marginVery weak

Among the 10% lowest rated companies in the industry

The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.

Debt to equityNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.

Liabilities to equityNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.

Efficiency & development

Equity to contributed capitalVery weak

Among the 10% lowest rated companies in the industry

Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.

One-year change in equityVery weak

Among the 10% lowest rated companies in the industry

The size of this year's increase or decrease in the company's equity.

One-year change in debtVery weak

Among the 10% lowest rated companies in the industry

The size of this year's increase or decrease in the company's debt.

Asset turnoverNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Revenue relative to total assets — the ability to generate revenue from the asset base.

Inventory turnoverNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.

Annual reports & filings

Annual report 2025
Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
View PDF
Annual report 2024
Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
View PDF
Annual report 2023
Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
View PDF
Annual report 2022
Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
View PDF
Annual report 2021
Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
View PDF

People & ownership

Management

Actively employed in the business

Name	Role	Member since
Current (1)
CH Christian Hölscher Management	Management	2020

Former (1)


IR Ian Rodney Laquian Chief Executive Officer	Chief Executive Officer	2018 – 2018

Board of directors

Non-executive oversight

Name	Role	Member since
Current (5)
MS Mikael Søndergaard Thomsen Board of Directors	Board of Directors	2023
IR Ian Rodney Laquian Chairman	Chairman	2023
CH Christian Hölscher Board of Directors	Board of Directors	2023
CE Claus Elsborg Olesen Board of Directors	Board of Directors	2023
JC John Connell Board of Directors	Board of Directors	2023

Shareholders

Active legal owners

Shareholder	Type	Ownership	Votes	Registered
JUMIKA Holdings ApS	Company	25–33.32%	25–33.32%	2026
Hoelscher Holdings Limited	Company	25–33.32%	25–33.32%	2026
MAC Clinical Research Finance Ltd.	Company	20–24.99%	20–24.99%	2026
Thomsen Pharma ApS	Company	5–9.99%	5–9.99%	2021
Ian Rodney Laquian	Individual	50–66.65%	50–66.65%	2018
Christian Hölscher	Individual	33.33–49.99%	33.33–49.99%	2018

Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.

One in three Danish companies experiences fraud

Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.

See the fraud module

Related companies

Company hierarchy

JUMIKA Holdings ApS25%

Thomsen Pharma ApS5%

Hoelscher Holdings Limited25%

MAC Clinical Research Finance Ltd.20%

Kariya Pharmaceuticals ApS (this company)

Board network connections

Board members of Kariya Pharmaceuticals ApS also hold positions in 13 other companies.

Person	Role here	Other companies
Claus Elsborg Olesen	Board of Directors	8 companiesMany roles
Mikael Søndergaard Thomsen	Board of Directors	3 companies
Ian Rodney Laquian	Chief Executive Officer	2 companies

Frequently asked questions

What is the CVR number of Kariya Pharmaceuticals ApS?

Kariya Pharmaceuticals ApS is registered with CVR / Virk under CVR 39270684.

What is the gross profit of Kariya Pharmaceuticals ApS?

Kariya Pharmaceuticals ApS reported a gross profit of -DKK 32.1m in 2025.

Who is the chairman of Kariya Pharmaceuticals ApS?

Ian Rodney Laquian chairs the board of Kariya Pharmaceuticals ApS, in role since 2023.

Where is Kariya Pharmaceuticals ApS headquartered?

Kariya Pharmaceuticals ApS's registered address is Ole Maaløes Vej 3.